Abstract: Slide Presentations |


James E. Hansen, MD, FCCP*; Xing-Guo Sun, MD; Karlman Wasserman, MD, PhD
Author and Funding Information

LA Biomedical Research Institute at Harbor/UCLA Medical Center, Torrance, CA


Chest. 2007;132(4_MeetingAbstracts):485b. doi:10.1378/chest.132.4_MeetingAbstracts.485b
Text Size: A A A
Published online


PURPOSE: To evaluate aerosolized bronchodilator (BD) therapy effectiveness, the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines treat FVC and FEV1 equally and require fixed increases in both volume (≥200 mL) and percentage (≥12%). Differently, we propose a statistical approach which compares three pre- and three post- BD spirometric trials for each patient and avoids fixed increases.

METHODS: After Institutional Review Board approval, we retrospectively analyzed one-year's pre-and post-BD forced spirometric trials for 313 consecutive clinical laboratory studies meeting ATS/ERS quality standards. We compared changes in FEV1, FEV3, and FVC from three pre-BD and three post-BD trials. Each study was classified as responsive or not according to ATS/ERS guidelines and independently according to our new individualized statistical approach. Primarily, our positive response required a statistically significant FEV1 improvement by an unpaired, single-tailed t-test at p<0.05 plus a similar improvement in FEV3 or FVC.

RESULTS: 135 studies were guideline and t-test non-responsive (true negative), 86 were guideline and t-test responsive (true positive), 89 were guideline non-responsive and t-test responsive (false negative) and 3 were guideline responsive and t-test non-responsive (false positive). Thus ATS/ERS guidelines missed more responders than they identified, especially patients with FEV1 <0.75L or >3.0L. The three false positive responders had large post-BD increases in FVC due to increased expiratory times without ATS/ERS or statistically significant increases in FEV1. Secondarily, FEV1 rank order statistics at p=0.05 agreed with t-tests 312/315 times.

CONCLUSION: ATS/ERS guidelines failed to detect positive bronchodilator response in 89 of 175 responders detected by an undemanding statistical analyses comparing pre- and post-BD measurements. More severely obstructed patients were especially penalized because they could not meet the ATS/ERS volume criteria.

CLINICAL IMPLICATIONS: This new statistical approach better informs clinicians of bronchodilator effectiveness.

DISCLOSURE: James Hansen, None.

Tuesday, October 23, 2007

2:30 PM - 4:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Bronchodilator therapy for chronic cough. Pulm Pharmacol Ther Published online May 17, 2017;
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543